



Cempra, Inc.  
 Investor Relations Department  
 6320 Quadrangle Drive Suite 360  
 Chapel Hill, NC 27517  
 United States

Visit IR website [↗](#)  
 Sign-up for email alerts [↗](#)

**NASDAQ: CEMP** <sup>1</sup>

Last Trade:	4.40
Trade Time:	4:00 PM ET Jun 28, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.55 - 26.95
Volume	N/A
Market Cap. (\$M)	231.000
Shares Out (M)	52.500

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Two lead antibacterial products, both in the treatment of infectious diseases, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

*Jun 2, 2017*  
[Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media](#)

*Jun 2, 2017*  
[Cempra to Present at the Jefferies 2017 Global Healthcare Conference](#)

*May 10, 2017*  
[Cempra Presents Data on Ophthalmic Solithromycin at ARVO](#)

*Apr 28, 2017*  
[Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update](#)

*Apr 21, 2017*  
[Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Feb 28, 2017*  
[Annual Report \(10-K\)](#)

*Apr 6, 2016*  
[Definitive Proxy Statement](#)

*Apr 28, 2017*  
[Quarterly Report \(10-Q\)](#)

*Oct 27, 2016*  
[Quarterly Report \(10-Q\)](#)

*Aug 1, 2016*  
[Quarterly Report \(10-Q\)](#)